


Figure 1. Scatter plots of baseline body weight by modal perampanel dose indicating TEAEs of (A) somnolence, (B) dizziness, and (C) irritability split by patients with and without these TEAEs who completed or discontinued during the Core and Extension A Phases (Safety Analysis Set)

- ● ● Patients with TEAE who completed

◆ ◆ ◆ Patients with TEAE who discontinued

■ ■ ■ Patients without TEAE who completed

▲ ▲ ▲ Patients without TEAE who discontinued



TEAE, treatment-emergent adverse event